Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 34,200 shares, a growth of 9.6% from the September 15th total of 31,200 shares. Approximately 2.3% of the shares of the company are short sold. Based on an average daily trading volume, of 2,560,000 shares, the short-interest ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Galmed Pharmaceuticals in a research note on Wednesday, October 9th. They issued a “sell” rating on the stock.

Galmed Pharmaceuticals Price Performance

Shares of NASDAQ GLMD traded down $0.18 during midday trading on Thursday, reaching $3.46. The company’s stock had a trading volume of 439,167 shares, compared to its average volume of 842,819. Galmed Pharmaceuticals has a 12-month low of $2.73 and a 12-month high of $23.80. The firm has a 50 day moving average price of $4.71 and a 200-day moving average price of $4.36. The stock has a market capitalization of $17.46 million, a P/E ratio of -1.43 and a beta of 0.73.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its quarterly earnings data on Wednesday, August 28th. The biopharmaceutical company reported $2.16 EPS for the quarter.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.